Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
A Phase II Trial of Personalized Immunotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck That Have Progressed on Prior Immunotherapy
Sponsor: Bristol-Myers Squibb
Listed as NCT04326257, this PHASE2 trial focuses on Squamous Cell Carcinoma of the Head and Neck and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 13 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Mar 2024 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Sep 2022 — Aug 2023 [monthly]
Recruiting PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Dan Zandberg
For direct contact, visit the study record on ClinicalTrials.gov .